,23 The definitive role of adding an ICI to a standard chemotherapy-based regimen in patients with an EGFR-mutated tumor awaits the results from several randomized trials (the phase 3 CheckMate 722 [NCT02864251] comparing chemotherapy plus nivolumab with chemotherapy alone, KEYNOTE 789 [NCT03515837] comparing pemetrexed plus a platinum with or without pembrolizumab, and the randomized phase 2 trial TH-138 [NCT03786692] evaluating the three-drug regimen of pemetrexed, carboplatin, and bevacizumab to the four-drug regimen of pemetrexed, carboplatin, bevacizumab, and atezolizumab). The gene discussed is EGFR; the disease is neoplasm.